THiogenesiS THerapeuticS

Strong Orphan Platform + Rapid Clinical Path

TTI-0102: Next-generation cysteamine prodrug

(TSXV: TTI / OTCQX: TTIPF)

December - 2025

Forward Looking Statement

This document and any attachments are intended for information purposes only and should not be construed as on offer or solicitation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain securities laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words "expected to" "illustrate" "has the potential to" "will be", "evaluating" "plans" "can be" "planning" "to predict" "potential" "may" "should" and words and expressions of similar import, are intended to identify forward-looking statements.

Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statement or the scientific data presented as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

Thiogenesis - Summary

Clinical-stage biotech developing novel thiol-based (~SH) prodrugs for high-need pediatric and orphan diseases

- **Leveraging decades of human data with** cysteamine (~SH) across multiple diseases, de-risked mechanisms of action and well understood biology
- **Lead Compound TTI-0102**, is an improved cysteamine-based prodrug that depletes cystine and targets improvements in oxidative stress & mitochondrial dysfunction
- **Planning for Phase 3 in cystinosis** and Phase 2 in pediatric MASH, plus two active clinical programs in inherited mitochondrial disease
- Multiple near-term catalysts across 2026 and into 2027
- **Compelling Valuation:** < C$35m with multiple value-creating catalysts

Experienced Leadership

Christopher M. Starr, PhD
Chairman of the Board

- Co-founder, BioMarin; co-founder & CEO of Raptor *(acquired for $800M),* Co-founder and Executive Chairman, Monopar
- 30+ years of experience building transformative orphan drug companies

Patrice Rioux, MD, PhD
Founder, CEO, Director

- Leading authority in mitochondrial metabolism
- Former CMO / Head of Regulatory at Raptor; *led approval of Procysbi®*
- Clinical development leadership across rare and metabolic disorders

Brook Riggins, CFA
CFO, Director

- 25+ years in small-cap public markets, focused on biotech and med-tech
- Leadership roles across investment firms and public life-science companies (CIO, VP Finance, VP - Research Analyst)

Thiogenesis - Investment Highlights

- **Clinically validated biology:** cysteamine-based drugs used in thousands of patients & numerous studies; strong glutathione(GSH)/antioxidant rationale
- **Next generation cysteamine prodrug:** with improved GI tolerability + controlled sustained release, improves adherence and dosing flexibility
- **505(b)(2)** enables accelerated development and lowers cost across all indications
- **De-risked indications:** with clear regulatory pathways (Cystinosis, MELAS, Leigh syndrome and pediatric MASH)
- **Efficient capital plan:** multiple milestones achievable with modest spend
- **Leadership with multiple prior orphan-drug approvals** *(including Procysbi® - delayed release cysteamine)*

TTI-0102 - Lead Compound



- **Asymmetric disulfide prodrug** that produces 2 cysteamine molecules + pantothenic acid (B5)
- **Controlled metabolic activation** → reduces peak-related GI related side effects common with existing cysteamine-based compounds
- ***Extended PK*** *provides potential for once-daily dosing, improving adherence and real-world use in chronic pediatric diseases*
- **Boosts intracellular cysteine,** enabling increased GSH and taurine to support mitochondrial function & neuronal stability
- **Applicable across multiple indications** where *oxidative stress, cysteine deficiency, and mitochondrial dysfunction* are key drivers

TTI-0102 (Phase 1)

A controlled-release next-generation cysteamine prodrug

Phase 1 Study (PK/Safety)



Well-tolerated at 4x *therapeutic dosing level of generic cysteamine in Phase 1 (healthy adult volunteers)*

Nephropathic Cystinosis

Cystinosis: Established biology with clear Phase 3 path



Disease Biology

- Defective lysosomal transporter → toxic cystine crystal accumulation & progressive organ damage (i.e. kidneys)
- Cysteamine is clinically proven but limited by **GI intolerance and strict multi-dose schedules**

TTI-0102 Rationale

- Designed for **improved tolerability** & **once-daily dosing potential**

Commercial Opportunity

- >$300M addressable market
- ***Near-term Phase 3: IND planned for H1-2026***

Besouw M - Adapted from et al. Drug Discovery Today, 2013

Leigh Syndrome Spectrum (LSS)

One of the most severe pediatric mitochondrial diseases

- Devastating early-onset mitochondrial disorder; ~1:40,000 live births
- Characterized by energy failure → developmental regression, motor loss, seizures
- ***TTI-0102*** addresses oxidative stress + low GSH/taurine implicated in neuronal and metabolic dysfunction
- **FDA-cleared IND (June 2025)** for a two-stage Phase 2a trial, in collaboration with a leading pediatric hospital
- ***Two-stage Phase 2a:***
  - Stage 1: randomized, placebo-controlled (9 pts)
  - Stage 2: pediatric open-label extension (6 pts)
- Dosing strategy incorporates ***MELAS interim biomarker data***

MELAS

(Mitochondrial Encephalomyopathy, Lactic Acidosis & Stroke Like Episodes)

MELAS: Strong biological rationale + Phase 2 underway

- Severe pediatric mitochondrial disease with rapid neurodegeneration; ~ 4.1/100,000 prevalence
- Driven by oxidative stress, low GSH, impaired energy metabolism
- ***TTI-0102*** reduces oxidative stress and supports neuronal stability
- Phase 2 EU trial (NL + FR): randomized, blinded, placebo-controlled
- *Interim analysis: biological proof-of-concept, mitochondrial biomarker improvements, dosing insights*
- **Final 6-month data expected January 2026**

Pediatric-Metabolic Dysfunction-Associated Steatohepatitis (MASH)



- ~2-3% prevalence; driven by obesity, oxidative stress and mitochondrial dysfunction
- **Primary mechanism:** reduces mitochondrial oxidative stress and helps metabolize liver fat
- **Secondary mechanisms (fibrosis):**
  - Cystine depletion
  - Pantothenic acid (B5)
- **NIH-CyNCh Trial** (DR-cysteamine) showed promising fat lowering signals - limited by dosing
- *TTI-0102 overcomes prior dosing limitations*
- ***IMPD submission planned to initiate a Phase 2 (EU)***

Thiogenesis – Upcoming Milestones

Potential milestones (6 months):

Cystinosis	→	Phase 3 IND clearance H2-2026
Leigh syndrome	→	Phase 2a patient enrollment Q1-26/data Q3-26
MELAS	→	Final Phase 2 data Q1-2026
Pediatric MASH	→	Phase 2 IMPD cleared H1-2026

Thiogenesis Pipeline



Company Info

Thiogenesis Therapeutics	(TSXV: TTI / OTCQX: TTIPF)
Shares Issued	51.8 million
Shares Fully Diluted	56.9 million
Insiders (32%)	16.7 million
Share Price (12/05/2025)	$0.64
52 week high/low	$0.88/C$0.51
Market Cap.	$33.2 million
Cash (09/30/2025)	$3.3 million
Contact	info@thiogenesis.com

- Currency in Canadian dollars

Companies of Interest

Name	Symbol	Disease	Stage	Market Cap	Notes
Thiogenesis	***TTI***	***MELAS***	***Ph.2***	***C$34 mn***	***Anti-ox, Anti-inflam.***
Spruce	SPRB	MPS IIIb	Ph. 2	US$107 mn	Enz. Replacement
Sagimet	SGMT	Obesity/NASH	Ph 2	US$224 mn	FASN
Larimar	LRMR	F. Ataxia	Ph. 2	US$302 mn	Protein Replacement
Zevra	ZVRA	NP-C	NDA	US$475mn	Enz. Signaling
Monopar	MNPR	Wilson's	NDA	US$575 mn	Copper chelation
Reata	*RETA*	*F. Ataxia*	*Approved*	*US$7.0 bn*	*Anti-ox & Anti-inflam.*